Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Multidrug-resistant tuberculosis.

Chai SJ, Rao CY, Varma JK.

N Engl J Med. 2012 Nov 29;367(22):2154-5; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA2. No abstract available.

PMID:
23190230
2.

Multidrug-resistant tuberculosis.

Spigelman M, Compton C, Gheuens J; Critical Path to TB Drug Regimens.

N Engl J Med. 2012 Nov 29;367(22):2155; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA3. No abstract available.

PMID:
23190231
3.

Multidrug-resistant tuberculosis.

D'Ambrosio L, Centis R, Migliori GB.

N Engl J Med. 2012 Nov 29;367(22):2154; author reply 2155-6. doi: 10.1056/NEJMc1210001#SA1. No abstract available.

4.

Confronting multidrug-resistant tuberculosis.

Chaisson RE, Nuermberger EL.

N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478. No abstract available.

PMID:
22670908
5.

[Tuberculosis: new treatment options and updated recommendations].

Schaberg T.

Dtsch Med Wochenschr. 2013 Apr;138(14):725-7. doi: 10.1055/s-0032-1332867. Epub 2013 Mar 26. Review. German. No abstract available.

PMID:
23533039
6.

[New antitubercular agents are not where where we need them to be].

Nau JY.

Rev Med Suisse. 2015 Dec 16;11(499):2408-9. French. No abstract available.

PMID:
26852561
7.

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis.

Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC.

N Engl J Med. 2015 Nov 12;373(20):1986-8. doi: 10.1056/NEJMc1505196. Erratum in: N Engl J Med. 2015 Dec 17;373(25):e29. Stuckia, David [corrected to Stucki, David].

8.

Delamanid: first global approval.

Ryan NJ, Lo JH.

Drugs. 2014 Jun;74(9):1041-5. doi: 10.1007/s40265-014-0241-5. Review.

PMID:
24923253
9.

Drug-resistance mechanisms and tuberculosis drugs.

Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME.

Lancet. 2015 Jan 24;385(9965):305-7. doi: 10.1016/S0140-6736(14)62450-8. No abstract available.

10.

Barriers to new drug development in respiratory disease.

Brigden G, du Cros P, Wong S.

Eur Respir J. 2016 Jan;47(1):356-7. doi: 10.1183/13993003.00783-2015. No abstract available.

11.

The worldwide epidemic of multidrug-resistant tuberculosis.

The Lancet Infectious Diseases.

Lancet Infect Dis. 2011 May;11(5):333. doi: 10.1016/S1473-3099(11)70105-0. No abstract available.

PMID:
21530885
12.

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.

Furin J, Brigden G, Lessem E, Rich M, Vaughan L, Lynch S.

Emerg Infect Dis. 2016 Mar;22(3). doi: 10.3201/eid2203.151430.

13.

Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.

Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, Mosidi T, Reed C, Seaworth B, Stillo J, Tisile P, von Delft D.

Int J Infect Dis. 2015 Mar;32:56-60. doi: 10.1016/j.ijid.2014.12.012. Review.

14.

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD.

Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27.

15.

Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.

Zhang Q, Liu Y, Tang S, Sha W, Xiao H.

Cell Biochem Biophys. 2013;67(3):957-63. doi: 10.1007/s12013-013-9589-5.

PMID:
23546935
16.

New drug combination may shorten tuberculosis treatment, study says.

Mayor S.

BMJ. 2015 Mar 18;350:h1518. doi: 10.1136/bmj.h1518. No abstract available.

PMID:
25788408
17.

New effective antituberculosis regimens.

Sotgiu G, Migliori GB.

Lancet. 2015 May 2;385(9979):1703-4. doi: 10.1016/S0140-6736(14)62303-5. Epub 2015 Mar 18. No abstract available.

PMID:
25795077
18.

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid.

Wells CD, Gupta R, Hittel N, Geiter LJ.

Eur Respir J. 2015 May;45(5):1498-501. doi: 10.1183/09031936.00176314. Epub 2015 Feb 19. No abstract available.

19.

Delamanid for Extensively Drug-Resistant Tuberculosis.

Gupta R, Geiter LJ, Wells CD, Gao M, Cirule A, Xiao H.

N Engl J Med. 2015 Jul 16;373(3):291-2. doi: 10.1056/NEJMc1415332. No abstract available.

20.

OPC-67683.

[No authors listed]

Tuberculosis (Edinb). 2008 Mar;88(2):132-3. doi: 10.1016/S1472-9792(08)70017-9. Review. No abstract available.

PMID:
18486051

Supplemental Content

Support Center